This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by JOHANSEN, J. S. Articles by CHRISTIANSEN, C. Search for Related Content PubMed PubMed Citation Articles by JOHANSEN, J. S. Articles by CHRISTIANSEN, C.

Serum Bone Gla Protein: A Potential Marker of Growth Hormone (GH) Deficiency and the Response to GH Therapy

Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, and the Department of Clinical Research, Novo-Nordisk (L.R.) Gentofte, Denmark
the Department of Pediatrics, University of Zurich (M.Z.) Zurich, Switzerland

Address all correspondence and requests for reprints to: Julia Sidenius Johansen, Department of Clinical Chemistry, Glostrup Hospital, DK2600 Glostrup, Denmark.

Serum bone Gla protein (BGP), a sensitive and specific biochemical marker of bone formation, was measured in 66 children deficient in GH before and after 3, 6, 9, and 12 months of treatment with biosynthetic human GH. Initial serum BGP levels were significantly lower than those of normal age-matched children. After 3 months of treatment, the mean serum BGP level had increased to normal. There was no relation between baseline serum BGP and the growth response, but the GH-induced increment in serum BGP levels at 3 months was highly significantly related to growth response after 12 months of therapy. The study shows that serum BGP could be a helpful biochemical marker in prediction of the growth response to long term GH therapy.

Received September 13, 1989.

This article has been cited by other articles:

				J. O. Sanders, R. H. Browne, S. J. McConnell, S. A. Margraf, T. E. Cooney, and D. N. Finegold Maturity Assessment and Curve Progression in Girls with Idiopathic Scoliosis J. Bone Joint Surg. Am., January 1, 2007; 89(1): 64 - 73. [Abstract] [Full Text] [PDF]

				K.-C. Leung, G. Johannsson, G. M. Leong, and K. K. Y. Ho Estrogen Regulation of Growth Hormone Action Endocr. Rev., October 1, 2004; 25(5): 693 - 721. [Abstract] [Full Text] [PDF]

				W. M. Drake, P. V. Carroll, K. T. Maher, K. A. Metcalfe, C. Camacho-Hubner, N. J. Shaw, D. B. Dunger, T. D. Cheetham, M. O. Savage, and J. P. Monson The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1658 - 1663. [Abstract] [Full Text] [PDF]

				C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text]

				A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]

				M. Cioffi, A. M. Molinari, P. Gazzerro, B. Di Finizio, M. Fratta, A. Deufemia, and G. A. Puca Serum Osteocalcin in 1634 Healthy Children Clin. Chem., March 1, 1997; 43(3): 543 - 545. [Full Text]

				D. M. Wilson, P. D. K. Lee, A. H. Morris, E. O. Reiter, J. M. Gertner, R. Marcus, V. E. Quarmby, and R. G. Rosenfeld Growth Hormone Therapy in Hypophosphatemic Rickets Arch Pediatr Adolesc Med, October 1, 1991; 145(10): 1165 - 1170. [Abstract] [PDF]